LONG-TERM FOLLOW-UP OF HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON ALFA: RELATION TO POLYMORPHISMS IN IL28B AND APOLIPOPROTEIN E LOCI (INTERFERLONG STUDY)

LONG-TERM FOLLOW-UP OF HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON ALFA: RELATION TO POLYMORPHISMS IN IL28B AND APOLIPOPROTEIN E LOCI (INTERFERLONG STUDY) - Response to interferon in hepatitis B: relation to IL28b and Apo E

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39063

Enrollment

135

Registered

2013-03-12

Start date

2013-04-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B liver inflammation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: chronic hepatitis B treated with interferon

Exclusion criteria

Exclusion criteria: coinfections with HIV, HCV

Design outcomes

Primary

Measure	Time frame
IL28b & Apo E genotype --> HBeAg and HBsAg loss.	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results